Open Label, Safety and Efficacy Study of QRX003 Lotion in Subjects With Netherton Syndrome

NCT05789056 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

RECRUITING

Status

20

Enrollment

INDUSTRY

Sponsor class

Conditions

Netherton Syndrome

Interventions

DRUG: QRX003, 4% Lotion

Sponsor

Quoin Pharmaceuticals